Health policy experts discuss politics, policy, and the impact on manufacturers heading into 2022.
- The reconciliation package, now known as the Build Back Better Act, that’s under fierce negotiation on Capitol Hill will influence drug pricing policies on several fronts. Since the recording of the panel, the Build Back Better (BBB) legislation passed in the House of Representatives and now heads
to the Senate for further negotiations, which will take place throughout the month of December. Congressional Democrats’ goal is to sign the bill into law by the end of 2021.
- State legislative actions around drug pricing are dominating the policy landscape, potentially impacting stakeholders throughout the healthcare supply chain
- There are several policy changes under consideration outside of drug pricing that will have a direct impact on manufacturers
- AmerisourceBergen continues to advocate for public policies that create healthier futures by ensuring a secure, efficient supply chain
Enter your information below to read more from the panel discussion featuring speakers:
Ashley O’Sullivan, Director, Government Affairs
Cristina Munoz, Senior Director, State Government Affairs
Emily Bondarenko, Director, Global Pricing Strategy